Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Dec 3, 2012

Keywords

ClinConnect Summary

This clinical trial, titled "Impact of ICCAN on Cancer Treatment Completion and Quality of Life," is exploring a new program called ICCAN to see if it helps cancer patients complete their treatment and improve their quality of life compared to standard hospital services. The study is open to cancer patients aged 21 to 80 who are currently undergoing chemotherapy or radiation therapy or are scheduled to start treatment soon. Participants should speak English, Spanish, or Mandarin and plan to stay in the area for at least a year.

If you decide to join, you will be part of a one-year study where you'll receive support either through the ICCAN program or the usual hospital services. Your experience will be important for understanding how these programs can benefit patients like you. It's also crucial to know that people with serious mental health issues or cognitive impairments won't be eligible to participate. Overall, this trial aims to find new ways to support cancer patients during their treatment journey.

Gender

ALL

Eligibility criteria

• Participant Inclusion Criteria:
• • Patient is eligible if he/she is
• • fluent in English, Spanish, or Mandarin
• • between the ages of 21-80 years old
• • cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
• • scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
• • planning on remaining in the area for at least 1 year
• Clinician is eligible if he/she:
• • Has an MD or DO degree
• • Is the treating physician providing care to a patient enrolled to the study
• ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:
• • Is 18 - 85 years of age
• • Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
• • Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
• • Is treated in the NY metropolitan area
• • Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income \< 200% of federal poverty level)
• • Has English or Spanish proficiency
• • Agrees to be audio-recorded
• ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:
• • Is 18 - 85 years of age
• • Has stage II-III TNBC
• • Treated at MSK Manhattan or OneMSK regional sites
• • Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income \< 200% of federal poverty level)
• • Has English or Spanish proficiency
• • Agrees to be audio-recorded
• ICCAN-IO process evaluation study team participants only:
• • Staff member who serves as an Access Facilitator
• • Agrees to be audio-recorded
• Participant Exclusion Criteria:
• Patient is ineligible is he/she is:
• • Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
• ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:
• • Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
• • Participants or family members who are participating in MSK IHCD studies related to social determinants of health
• ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:
• • Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
• • Participants or family members who are participating in MSK IHCD studies related to social determinants of health